4. Effects of keloid properties on treatment efficacy 107 4. Total no. keloid patients: 90. Mourad et al., 2016 Duration, etiology, location A: IL cryotherapy; B: cryospray - Duration: negative correlation between keloid duration and treatment efficacy. - Etiology and location: NS. Swada and Sone scoring Mean duration (months): NR Etiology: acne (n=16), burn (n=18), surgery (n=7), trauma (n=8), vaccine (n=2). Location: ear (n=10), face/scalp (n=8), chest (n=7), extremities (n=6), abdomen (n=4), and neck (n=4). Total no. keloid patients: 50. Neinaa et al., 2021 Baseline VSS, duration, size A: IL BTX-A; B: IL PRP C: IL TCA - Duration and size: NS. - Baseline VSS: Higher baseline VSS scores were significantly correlated to better treatment outcomes in all studied groups (BTX-A and PRP were the most efficacious treatments). VSS score Mean duration (months): 5.2 (n=20), 8.4 (n=20), 7.4 (n=20). Mean baseline VSS: 9.4 (n=20), 9.7 (n=20), 8.8 (n=20). Mean size (cm2): 7.6 (n=20), 8.4 n=20), 7.4 (n=20). Total no. keloid patients: 60. Rani et al., 2022 Duration, location A: IL TCA, B: IL 5FU, C: cryotherapy + IL TCA, D: surgical excision + topical 5% imiquimod - Duration: negative correlation between keloid duration and treatment efficacy. Lesions of < 2 years showed better efficacy than lesions of >2 years (p < 0.05). - Location: ‘excellent response’ on earlobes, face and back. Poor efficacy on chest and shoulder (p<0.05). Unclear Duration: <1 year (n=42), 1-2 year (n=16), >2 year (n=22). Location: chest (n=38), earlobes(n=16), shoulders (n=11), face (n=1). Total no. keloid patients: 80. Saha et al., 2012 Duration, location, no. of lesions A: IL 5-FU; B: IL TCA -Duration, location and number of lesions: NS. Keloid volume Duration: : ≤ 2 years (n=22), > 2years (n=22). No of lesions (range): 1-6 (n=NR). Locations: arms (n=NR), back (n=NR), chest (n=NR). Total no. keloid patients: 44.
RkJQdWJsaXNoZXIy MTk4NDMw